QR kód

Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency

Abstract Background Renal insufficiency is one of the most common complications in the treatment of multiple myeloma (MM). The administration of isatuximab showed improved patient outcome regarding the occurrence of renal insufficiency. Building on the results of the ICARIA-MM study, the aim of this...

Celý popis

Uloženo v:
Hlavní autoři: F. Jakobs, P. Ahmadi, V. Osterkamp, J. Jeck, U. Holtick, C. Scheid, Florian Kron
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2025-03-01
Edice:Cost Effectiveness and Resource Allocation
Témata:
Multiple myeloma
Renal insufficiency
Cost savings
Isatuximab
Hospital management
On-line přístup:https://doi.org/10.1186/s12962-024-00600-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky